Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
63.15
-1.12 (-1.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Gilead Sciences
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Merck Teams Up With Five Indian Generic Players To Expand COVID-19 Drug Access, Production
April 27, 2021
Merck & Co Inc (NYSE: MRK) has partnered with five Indian generic drugmakers to expand production and access to Molnupiravir, its experimental oral...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
April 27, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ...
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
The Smartest Stocks to Buy With $1,000 Right Now
April 26, 2021
These fundamentally strong stocks can yield solid returns in the coming years.
Via
The Motley Fool
Topics
Electric Vehicles
Exposures
Electric Vehicles
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
April 24, 2021
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:...
Via
Benzinga
Exposures
Product Safety
Should You Buy Gilead Sciences in April?
April 21, 2021
Gilead Sciences had a stellar 2020, but this year is looking a little more perilous.
Via
The Motley Fool
The Daily Biotech Pulse: Quidel Slides On Negative Pre-Announcement, Roche Gets Positive EMA Committee Recommendation, 3 IPOs
April 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 22) AtriCure, Inc. (NASDAQ:...
Via
Benzinga
7 Health Care Stocks Showing Unusual Options Activity In Today's Session
April 19, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...
Via
Benzinga
Why Tonix Pharmaceuticals Stock Is Jumping Today
April 19, 2021
The company struck a deal to bolster its COVID-19 pipeline.
Via
The Motley Fool
Exposures
COVID-19
Humanigen's Lenzilumab Shows Encouraging Response Rate In Blood Cancer Study
April 19, 2021
Humanigen Inc (NASDAQ: HGEN) has announced data from the Phase 1b portion of the ZUMA-19 trial evaluating its lead candidate lenzilumab in patients...
Via
Benzinga
What Does Gilead Sciences Debt Look Like?
April 19, 2021
Shares of Gilead Sciences (NASDAQ:GILD) fell by 0.30% in the past three months. Before we understand the importance of debt, let us look at how much debt Gilead Sciences...
Via
Benzinga
SPACs Attack Recap: 5 Deals, Rumors And Headline News
April 18, 2021
It was another busy week for the SPAC market with numerous deal announcements and rumored deals. Benzinga's "SPACs Attack" covered it all throughout the week. Here...
Via
Benzinga
Could Vir Biotechnology Be a Millionaire Maker Stock?
April 17, 2021
Vir is developing treatments in billion-dollar markets.
Via
The Motley Fool
Exposures
COVID-19
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
April 16, 2021
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...
Via
Benzinga
Cancer Biotech Tango Therapeutics Picks Boxer Capital's SPAC To Go Public Via $353M Merger
April 14, 2021
The latest biotech-SPAC deal has arrived with Cambridge, Massachusetts-based Tango Therapeutics announcing its reverse merger with Boxer Capital’s ...
Via
Benzinga
Drugmakers Are Vying for a Multibillion-Dollar Market
April 14, 2021
Too bad there are issues with side effects.
Via
The Motley Fool
A Peek Into The Markets: US Stock Futures Edge Higher; Bank Earnings In Focus
April 14, 2021
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the Nasdaq jumped over 1% in the previous session. Investors are awaiting earnings...
Via
Benzinga
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
April 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (...
Via
Benzinga
Exposures
Product Safety
How To Play Lagging Healthcare Stocks
April 13, 2021
The Healthcare Select SPDR Fund (XLV) gives you the most diversified play in healthcare returning 11.4% in ’20 and 4% YTD.
Via
Talk Markets
Biotech Stocks Could Use A Win — Will The First Quarter Offer That?
April 08, 2021
Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday.
Via
Investor's Business Daily
A Look Into Gilead Sciences Price Over Earnings
April 08, 2021
Looking into the current session, Gilead Sciences Inc. (NASDAQ:GILD) shares are trading at $65.61, after a 0.1% increase. Moreover, over the past month, the stock...
Via
Benzinga
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
April 08, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc...
Via
Benzinga
Exposures
Product Safety
Is Gilead Sciences Stock a Buy?
April 08, 2021
This is one contrarian investment you don't want to miss out on.
Via
The Motley Fool
Gilead's Trodelvy Wins FDA Regular Approval For Triple-Negative Breast Cancer
April 08, 2021
The FDA has granted regular approval to Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan) for an aggressive and tough-to-treat...
Via
Benzinga
Exposures
Product Safety
Exclusive: Precigen's CEO Breaks Down Biotech's Oncology Platforms, Technology, Differentiators
April 06, 2021
Cancer treatment has evolved from the use of chemotherapeutic anti-tumor drugs to targeted therapies to monoclonal antibodies to immunotherapies to new, personalized therapeutics...
Via
Benzinga
< Previous
1
2
...
25
26
27
28
29
30
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.